Lead Sponsor

University of Michigan

Collaborators

Age

18 - 74 years

Sex

ALL

Healthy Volunteers

No

•18-74 years of age
•Within 50% of ideal body weight and greater than 40 kg
•Chronic kidney disease (CKD) stage 5 receiving maintenance hemodialysis for at least 3 months
•Native kidney estimated glomerular filtration rate(GFR) \< 10 mL/min
•No concurrent illness or evidence of infection
•Able to give informed consent

•QTc interval \> 470 msec at echocardiogram (ECG) obtained within the last 6 months
•Concomitant QT-prolonging drugs, major P-gp inhibitors, and CYP3A4 inducers and inhibitors including: cyclosporine, rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. John's Wort, ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, saquinavir, quinidine, dofetilide, sotalol, amiodarone, erythromycin, thioridazine, ziprasidone, haloperidol, trimethoprim/sulfamethoxazole, ciprofloxacin, norfloxacin, levofloxacin, moxifloxacin
•Pre-study hemoglobin \< 9.5 g/dL
•Plasma albumin \< 2.5 g/dL
•Liver disease - exclude subjects with a Child Pugh score of C or higher
•Positive pregnancy test
•Breastfeeding
•Allergy to ranolazine
•Participating in another investigational study
•Hepatitis B infection due to dialysis isolation requirements
•Unstable blood pressure control
•Need for routine large fluid removal during dialysis (\> 4L)